Cite

HARVARD Citation

    Davar, D. et al. (2017). High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. Journal for immunotherapy of cancer. 5 (1), p. . [Online]. 
  
Back to record